42
Participants
Start Date
February 19, 2015
Primary Completion Date
September 14, 2016
Study Completion Date
July 30, 2017
Atuveciclib, BAY1143572
The starting dose was 20 mg BAY 1143572 once daily from Cycle 1 Day 1. Each cycle was defined as a period of 28 days. Dosing cycles continued until evidence of progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator.
Columbia University Medical Center, New York
Medical University of South Carolina, Charleston
Vanderbilt University Medical Center, Nashville
Universitätsklinikum der Johann Wolfgang Goethe Universität, Frankfurt am Main
Dana-Farber Cancer Institute, Boston
Hackensack University Medical Center, Hackensack
Medizinische Fakultät Carl Gustav Carus, Dresden
Lead Sponsor
Bayer
INDUSTRY